These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 28880683

  • 21. [RANKL as a target molecule for treatment of joint destruction].
    Tanaka S.
    Clin Calcium; 2007 Apr; 17(4):586-92. PubMed ID: 17404489
    [Abstract] [Full Text] [Related]

  • 22. Denosumab for joints and bones.
    Lewiecki EM.
    Curr Rheumatol Rep; 2009 Jul; 11(3):196-201. PubMed ID: 19604464
    [Abstract] [Full Text] [Related]

  • 23. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
    Ohtsuji M, Lin Q, Nishikawa K, Ohtsuji N, Okazaki H, Tsurui H, Amano H, Shirai T, Nishimoto N, Nishimura H, Hirose S.
    Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
    [Abstract] [Full Text] [Related]

  • 24. CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis.
    Tsushima H, Okazaki K, Ishihara K, Ushijima T, Iwamoto Y.
    Arthritis Res Ther; 2015 Feb 17; 17(1):31. PubMed ID: 25811130
    [Abstract] [Full Text] [Related]

  • 25. Pathogenic conversion of regulatory B10 cells into osteoclast-priming cells in rheumatoid arthritis.
    Hu F, Liu H, Liu X, Zhang X, Xu L, Zhu H, Li Y, Shi L, Ren L, Zhang J, Li Z, Jia Y.
    J Autoimmun; 2017 Jan 17; 76():53-62. PubMed ID: 27640100
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
    Ishiguro N, Tanaka Y, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D, Takeuchi T.
    Rheumatology (Oxford); 2019 Jun 01; 58(6):997-1005. PubMed ID: 30602032
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. IL-23 induces receptor activator of NF-kappaB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kappaB signal pathways.
    Li X, Kim KW, Cho ML, Ju JH, Kang CM, Oh HJ, Min JK, Lee SH, Park SH, Kim HY.
    Immunol Lett; 2010 Jan 04; 127(2):100-7. PubMed ID: 19900478
    [Abstract] [Full Text] [Related]

  • 29. Denosumab update.
    Lewiecki EM.
    Curr Opin Rheumatol; 2009 Jul 04; 21(4):369-73. PubMed ID: 19424068
    [Abstract] [Full Text] [Related]

  • 30. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
    Hu L, Liu R, Zhang L.
    Int Immunopharmacol; 2022 Oct 04; 111():109095. PubMed ID: 35926270
    [Abstract] [Full Text] [Related]

  • 31. miR-145-5p Increases Osteoclast Numbers In Vitro and Aggravates Bone Erosion in Collagen-Induced Arthritis by Targeting Osteoprotegerin.
    Chen Y, Wang X, Yang M, Ruan W, Wei W, Gu D, Wang J, Guo X, Guo L, Yuan Y.
    Med Sci Monit; 2018 Jul 30; 24():5292-5300. PubMed ID: 30059491
    [Abstract] [Full Text] [Related]

  • 32. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo.
    Kukita A, Kukita T, Nagata K, Teramachi J, Li YJ, Yoshida H, Miyamoto H, Gay S, Pessler F, Shobuike T.
    Arthritis Rheum; 2011 Sep 30; 63(9):2744-54. PubMed ID: 21590684
    [Abstract] [Full Text] [Related]

  • 33. [Expectation for alleviation of joint destruction in rheumatoid arthritis by new molecular targeting pharmaceutics including anti-rankle antibody].
    Nakamura T.
    Clin Calcium; 2009 Mar 30; 19(3):381-6. PubMed ID: 19252248
    [Abstract] [Full Text] [Related]

  • 34. Rheumatoid arthritis-associated bone erosions: evolving insights and promising therapeutic strategies.
    Yan M, Su J, Li Y.
    Biosci Trends; 2020 Nov 04; 14(5):342-348. PubMed ID: 32908076
    [Abstract] [Full Text] [Related]

  • 35. Promising bone-related therapeutic targets for rheumatoid arthritis.
    Choi Y, Arron JR, Townsend MJ.
    Nat Rev Rheumatol; 2009 Oct 04; 5(10):543-8. PubMed ID: 19798028
    [Abstract] [Full Text] [Related]

  • 36. IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis.
    Park MK, Her YM, Cho ML, Oh HJ, Park EM, Kwok SK, Ju JH, Park KS, Min DS, Kim HY, Park SH.
    Immunol Lett; 2011 Sep 30; 139(1-2):42-51. PubMed ID: 21620893
    [Abstract] [Full Text] [Related]

  • 37. Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-κB signalling pathway.
    Doss HM, Samarpita S, Ganesan R, Rasool M.
    Life Sci; 2018 Aug 15; 207():284-295. PubMed ID: 29908722
    [Abstract] [Full Text] [Related]

  • 38. New Insights into the Role of Synovial Fibroblasts Leading to Joint Destruction in Rheumatoid Arthritis.
    Matsuda K, Shiba N, Hiraoka K.
    Int J Mol Sci; 2023 Mar 08; 24(6):. PubMed ID: 36982247
    [Abstract] [Full Text] [Related]

  • 39. Erosive arthritis.
    Schett G.
    Arthritis Res Ther; 2007 Mar 08; 9 Suppl 1(Suppl 1):S2. PubMed ID: 17634141
    [Abstract] [Full Text] [Related]

  • 40. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J, García R, Garrido P, Isla D, Massuti B, Blanca B, Vázquez J.
    Clin Lung Cancer; 2015 Nov 08; 16(6):431-46. PubMed ID: 26264596
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.